Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis (Xolair CRS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2013 by Massachusetts General Hospital
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Ellen Dutta, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01066104
First received: February 8, 2010
Last updated: March 6, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2014
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)